Pharmacotherapy represents the first-line treatment in the management of most chronic and transient medical conditions warranting therapeutic intervention in the U.S.
This report examines the healthcare trends in Asia-Pacific countries (Japan, China, South Korea, India, Thailand, Vietnam, Malaysia and Australia), as well as analyzes and forecasts (toward 2019).
An estimated 200 million people in the United States (U.S.) experience some degree of neurological impairment over the course of a lifetime.
U.S. Markets for Obesity Drugs & Devices
The United States (U.S.) market for orthopedic extremity and soft tissue repair products encompasses interventional surgical procedures and biologic and synthetic implants used in the repair of bone, joints, and soft tissue that have been damaged as a result of disease or due to physical injury.
Bristol-Myers Squibb’s (BMS) Opdivo (nivolumab) has outpaced Merck’s Keytruda (pembrolizumab) primarily in non-small cell lung cancer (NSCLC) because of its early approval in squamous NSCLC, updated National Comprehensive Cancer Network (NCCN) guidelines in 2015,
The molecular diagnostic products market is the highest growth segment of the global in vitro diagnostics (IVDs) market valued at an estimated $5.3 billion in 2014 and projected to grow at a compound annual growth rate of 6.6% to $7.3 billion by the year 2019.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!